Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

Hepatitis C virus (HCV) infection is a major health problem with significant clinical and economic burdens in patients with chronic kidney disease (CKD) stage 4 or 5. Current guidelines recommend pan-genotypic direct-acting antivirals (DAAs) to be the first-line treatment of choice for HCV. This rev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology international 2022-10, Vol.16 (5), p.1001-1019
Hauptverfasser:	Liu, Chen-Hua, Kao, Jia-Horng
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents Antiviral Agents - adverse effects Antiviral drugs Chronic infection Colorectal Surgery Dialysis Drug Therapy, Combination Epidemiology Health services Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C, Chronic Hepatology Humans Kidney diseases Kidney transplantation Medical prognosis Medicine Medicine & Public Health Patients Preempting Public health Quinoxalines - therapeutic use Renal Insufficiency, Chronic Review Review Article Safety Sofosbuvir - therapeutic use Surgery Sustained Virologic Response Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!